TTI Stock Overview
A biopharmaceutical company, develops thiol-active therapeutic compounds to treat unmet pediatric medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Thiogenesis Therapeutics, Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.68 |
| 52 Week High | CA$1.06 |
| 52 Week Low | CA$0.52 |
| Beta | 0.59 |
| 11 Month Change | 1.49% |
| 3 Month Change | -6.85% |
| 1 Year Change | -15.00% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 36.00% |
Recent News & Updates
We're Keeping An Eye On Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Rate
Nov 20
We Think Thiogenesis Therapeutics (CVE:TTI) Needs To Drive Business Growth Carefully
Jul 17Recent updates
We're Keeping An Eye On Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Rate
Nov 20We Think Thiogenesis Therapeutics (CVE:TTI) Needs To Drive Business Growth Carefully
Jul 17Here's Why We're Not Too Worried About Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Situation
Aug 25We're Not Very Worried About Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Rate
May 01Shareholder Returns
| TTI | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 17.2% | -8.5% | 0.7% |
| 1Y | -15.0% | 1.5% | 21.7% |
Return vs Industry: TTI underperformed the Canadian Biotechs industry which returned -0.4% over the past year.
Return vs Market: TTI underperformed the Canadian Market which returned 21.4% over the past year.
Price Volatility
| TTI volatility | |
|---|---|
| TTI Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.6% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: TTI has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: TTI's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Patrice Rioux | www.thiogenesis.com |
Thiogenesis Therapeutics, Corp., a biopharmaceutical company, develops thiol-active therapeutic compounds to treat unmet pediatric medical needs. The company’s lead product candidate comprises TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke, other mitochondrial diseases, Rett syndrome, and pediatric non-alcoholic fatty liver diseases. Thiogenesis Therapeutics, Corp. is headquartered in Toronto, Canada.
Thiogenesis Therapeutics, Corp. Fundamentals Summary
| TTI fundamental statistics | |
|---|---|
| Market cap | CA$30.48m |
| Earnings (TTM) | -CA$4.09m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.6x
P/E RatioIs TTI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TTI income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$4.09m |
| Earnings | -CA$4.09m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.09 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TTI perform over the long term?
See historical performance and comparison